AstraZeneca

Anglo-Swedish pharmaceutical giant formed by merger, pioneering oncology treatments and co-developing one of the world's most widely deployed COVID-19 vaccines.

历史时间线

• 1999: Astra AB (Sweden) merges with Zeneca Group (UK) to form AstraZeneca
• 2007: Acquires MedImmune for $15.6B — enters biologics
• 2014: Rejects $120B Pfizer takeover bid
• 2020: Co-develops Oxford-AstraZeneca COVID-19 vaccine — 3B+ doses distributed globally
• 2020: Acquires Alexion for $39B — rare disease expansion
• 2022: Acquires Daiichi Sankyo partnership for Enhertu (breast cancer)
• 2023: $45B+ revenue; oncology = 40%+ of pipeline

商业模式

R&D-driven pharma with focus on oncology, cardiovascular, renal/metabolism, and respiratory/immunology. Revenue from prescription drug sales globally. Alexion acquisition adds rare disease (complement inhibitors). Oxford vaccine developed at-cost for pandemic, building long-term government relationships.

护城河分析

Oncology pipeline depth (Enhertu, Tagrisso, Imfinzi); Alexion's rare disease dominance (complement pathway); Oxford partnership for vaccine tech; strong presence in emerging markets (China, Asia); biosimilar strategy for post-patent products.

关键数据

• revenue: $45B+ (2023)
• oncology_share: 40%+ of pipeline
• vaccine_doses: 3B+ (Oxford-AZ vaccine)
• employees: ~90,000
• market_cap: ~$200B

有趣事实

The Oxford-AstraZeneca vaccine was unique in being developed at non-profit cost for low-income countries during the pandemic — AstraZeneca pledged not to profit from it during the emergency. The vaccine used a chimpanzee adenovirus vector (ChAdOx1) technology pioneered at Oxford University.